Please login to the form below

Not currently logged in
Email:
Password:

Sosei

This page shows the latest Sosei news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EULAR kicks off in Amsterdam, May brings together remainers and brexiteers and Autolus launches its IPOS

Daily Brief: EULAR kicks off in Amsterdam, May brings together remainers and brexiteers and Autolus launches its IPOS

Andrew Oakley had been appointed the firm's new chief financial officer, joining Sosei Group where he served as its executive vice president and chief financial officer since February 2017.

Latest news

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.

  • Deal Watch March 2017 Deal Watch March 2017

    20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Not disclosed. Staying in oncology, AstraZeneca closed an exclusive global licence with Heptares [owned by Sosei] securing a headline value of $510m. ... Acquisition– asset. 570. Heptares [Sosei]. AZ. HTL 1071 immuno‐ oncology small molecule and

  • Pharma deals in February 2015 Pharma deals in February 2015

    It came as no surprise therefore to learn of Sosei's acquisition of this UK biotech jewel with an upfront payment of $180m in cash and up to $220m in milestones.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor targeted drug candidates - Alzheimer's disease, metabolic disease, schizophrenia, migraine etc.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints CFO Sosei appoints CFO

    Sosei appoints CFO. Andrew Oakley joins the Tokyo-based pharma firm. Andrew Oakley has joined Tokyo-based pharmaceutical firm Sosei as chief financial officer, succeeding Hidetoshi Torami. ... Peter Bains, chief executive officer of Sosei, said: “

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    Sosei appoints chief operating officer. Peter Bains also takes on the role of representative executive officer. ... Tokyo, Japan-based Sosei has appointed Peter Bains as its chief operating officer and representative executive officer.

  • Dr David Chiswell joins Kymab Dr David Chiswell joins Kymab

    He brings over 30 years of biotechnology expertise to the firm, having held senior management positions at a number of pharmaceutical companies, including Arakis, Arrow Therapeutics, Daniolabs and Sosei.

More from appointments
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics